Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.

Levva S, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Papadopoulou K, Lakis S, Koukoulias K, Karavasilis V, Pentheroudakis G, Balassi E, Zagouri F, Kaklamanos IG, Pectasides D, Razis E, Aravantinos G, Papakostas P, Bafaloukos D, Rallis G, Gogas H, Fountzilas G.

Cancer Genomics Proteomics. 2017 May-Jun;14(3):181-195.

2.

Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.

Heublein S, Mayr D, Meindl A, Kircher A, Jeschke U, Ditsch N.

J Exp Clin Cancer Res. 2017 Apr 20;36(1):57. doi: 10.1186/s13046-017-0517-1.

3.

Urinary kallikrein 10 predicts the incurability of gastric cancer.

Shimura T, Ebi M, Yamada T, Yamada T, Katano T, Nojiri Y, Iwasaki H, Nomura S, Hayashi N, Mori Y, Kataoka H, Moses MA, Joh T.

Oncotarget. 2017 Apr 25;8(17):29247-29257. doi: 10.18632/oncotarget.16453.

4.

The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer.

Thomsen CEB, Appelt AL, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A.

Cancer Med. 2017 May;6(5):928-936. doi: 10.1002/cam4.1051. Epub 2017 Apr 4.

5.

Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients.

Barbano R, Pasculli B, Rendina M, Fontana A, Fusilli C, Copetti M, Castellana S, Valori VM, Morritti M, Graziano P, Luigi C, Coco M, Picardo F, Mazza T, Evron E, Murgo R, Maiello E, Esteller M, Fazio VM, Parrella P.

Sci Rep. 2017 Mar 27;7:45283. doi: 10.1038/srep45283.

6.

Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study.

Lea J, Sharma R, Yang F, Zhu H, Ward ES, Schroit AJ.

Oncotarget. 2017 Feb 28;8(9):14395-14407. doi: 10.18632/oncotarget.14795.

7.

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.

Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA; the TEXT principal investigators.

Breast Cancer Res. 2016 Nov 8;18(1):110.

8.

A three-molecule score based on Notch pathway predicts poor prognosis in non-metastasis clear cell renal cell carcinoma.

Liu Z, Fu Q, Fu H, Wang Z, Xu L, An H, Li Y, Xu J.

Oncotarget. 2016 Oct 18;7(42):68559-68570. doi: 10.18632/oncotarget.11849.

9.

Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers.

Dhingra R, Vasan RS.

Trends Cardiovasc Med. 2017 Feb;27(2):123-133. doi: 10.1016/j.tcm.2016.07.005. Epub 2016 Jul 28. Review.

PMID:
27576060
10.

Enhancement of Pathologist's Routine Practice: Reuse of DNA Extracted from Immunostained Formalin-fixed Paraffin-embedded (FFPE) Slides in Downstream Molecular Analysis of Cancer.

Al-Attas A, Assidi M, Al-Maghrabi J, Dallol A, Schulten HJ, Abu-Elmagd M, Chaudhary A, Abuzenadah A, Budowle B, Buhmeida A, Al-Qahtani M.

Cancer Genomics Proteomics. 2016 09-10;13(5):399-406.

11.

The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment.

Kim JY, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH, Park YH.

Sci Rep. 2016 Aug 22;6:31804. doi: 10.1038/srep31804.

12.

Welcome to Journal of Hepatocellular Carcinoma.

Kaseb AO.

J Hepatocell Carcinoma. 2015 Jan 9;2:1-2. doi: 10.2147/JHC.S60647. eCollection 2015. No abstract available.

13.

Association between demographic factors and prognosis in urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis.

Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH.

Oncotarget. 2017 Jan 31;8(5):7464-7476. doi: 10.18632/oncotarget.10708.

14.

A Systematic Review of Diagnostic Biomarkers of COPD Exacerbation.

Chen YW, Leung JM, Sin DD.

PLoS One. 2016 Jul 19;11(7):e0158843. doi: 10.1371/journal.pone.0158843. eCollection 2016.

15.

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review.

Green G, Carmona R, Zakeri K, Lee CH, Borgan S, Marhoon Z, Sharabi A, Mell LK.

PLoS One. 2016 Jul 6;11(7):e0156489. doi: 10.1371/journal.pone.0156489. eCollection 2016.

16.

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.

Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E, Gelber RD, Regan MM, Colleoni M.

Breast Cancer Res Treat. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2.

PMID:
27372069
17.

Gene Expression Profiling of Breast Cancer Brain Metastasis.

Lee JY, Park K, Lee E, Ahn T, Jung HH, Lim SH, Hong M, Do IG, Cho EY, Kim DH, Kim JY, Ahn JS, Im YH, Park YH.

Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623.

18.

Cholesterol Metabolism and Prostate Cancer Lethality.

Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR.

Cancer Res. 2016 Aug 15;76(16):4785-90. doi: 10.1158/0008-5472.CAN-16-0903. Epub 2016 Jun 20.

PMID:
27325648
19.

Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Szajnik M, Czystowska-Kuźmicz M, Elishaev E, Whiteside TL.

Expert Rev Mol Diagn. 2016 Aug;16(8):811-26. doi: 10.1080/14737159.2016.1194758. Epub 2016 Jun 23.

PMID:
27268121
20.

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.

Hida AI, Sagara Y, Yotsumoto D, Kanemitsu S, Kawano J, Baba S, Rai Y, Oshiro Y, Aogi K, Sagara Y, Ohi Y.

Breast Cancer Res Treat. 2016 Jul;158(1):1-9. doi: 10.1007/s10549-016-3848-2. Epub 2016 Jun 3.

Supplemental Content

Support Center